← Human Trials & Peer-Reviewed Studies
Nicotine restores functional connectivity of the ventral attention network in schizophrenia.
Plain-language guide to PMID 27085606 (2016): single-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 17 patients.
Key Facts
- PMID
- 27085606
- Journal
- Neuropharmacology
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Smucny J et al. (3 authors)
- DOI
- 10.1016/j.neuropharm.2016.04.015
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
This study is the first to examine the effects of nicotine on connectivity within the ventral attention network (VAN) during a selective attention task in schizophrenia.
Why It Was Studied
Effects of nicotine on resting state VAN connectivity were also examined.
Who Took Part
According to the abstract, 17 patients were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, single-blind, placebo-controlled and crossover.
The patients were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
In this single-blind Therapeutic nicotine (patch, non-peptide) study one party knew the assignments and the other did not.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
In the crossover set-up each of the patients took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Acoustic Stimulation, Attention, Brain, Magnetic Resonance Imaging, Nerve Net, Nicotine and Psychomotor Performance.
Author keywords: Connectivity, Schizophrenia, Ventral attention network and fMRI.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 17 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2016 (Neuropharmacology), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.